Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.37

+0.9%

Dec 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: XenaLives who wrote (3480)	4/20/2001 11:55:57 AM
From: Biomaven	Read Replies (2) of 52153

Paula, FDA wants to take DHEA off of over the counter That's an interesting angle I hadn't thought of. Certainly patients currently taking the drug would be safer than with their present OTC version of unknown potency and composition. OTOH, the FDA scientists might be reluctant to give their stamp of approval to a drug of uncertain efficacy. This would be a perfect case for an intermediate label - "safety OK, efficacy uncertain." Kind of like the Scottish criminal justice system, which adds "unproven" as a third possible verdict. (Really "Guilty, but the witnesses were too drunk to be reliable." <g>) Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next